Publicaciones en colaboración con investigadores/as de Hospital Universitario Virgen del Rocío (92)

2023

  1. Combination Therapy of Chemotherapy or Radiotherapy and the Neurokinin-1 Receptor Antagonist Aprepitant: A New Antitumor Strategy?

    Current Medicinal Chemistry, Vol. 30, Núm. 16, pp. 1798-1812

  2. Genetic Architecture of Ischaemic Strokes after COVID-19 Shows Similarities with Large Vessel Strokes

    International Journal of Molecular Sciences, Vol. 24, Núm. 17

  3. The Repurposing of Non-Peptide Neurokinin-1 Receptor Antagonists as Antitumor Drugs: An Urgent Challenge for Aprepitant

    International Journal of Molecular Sciences, Vol. 24, Núm. 21

  4. The imperative for quality control programs in Monkeypox virus DNA testing by PCR: CIBERINFEC quality control

    Journal of Medical Virology, Vol. 95, Núm. 11

2022

  1. Critical Requirement of SOS1 for Development of BCR/ABL-Driven Chronic Myelogenous Leukemia

    Cancers, Vol. 14, Núm. 16

  2. Involvement of the Substance P/Neurokinin-1 Receptor System in Cancer

    Cancers

  3. Regulation of zinc homeostatic genes by environmental pH in the filamentous fungus Aspergillus fumigatus

    Environmental Microbiology, Vol. 24, Núm. 2, pp. 643-666

  4. The Neurokinin-1 Receptor Is Essential for the Viability of Human Glioma Cells: A Possible Target for Treating Glioblastoma

    BioMed research international, Vol. 2022, pp. 6291504

  5. Why Use Aprepitant Only as a Cough Suppressant in Lung Cancer When at Higher Doses it Could Also Exert an Antitumor Action?

    Archivos de Bronconeumologia

2021

  1. Antibody response in patients admitted to the hospital with suspected SARS-CoV-2 infection: results from a multicenter study across Spain

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 40, Núm. 6, pp. 1343-1349

  2. The first wave of the COVID-19 epidemic in Spain was associated with early introductions and fast spread of a dominating genetic variant

    Nature Genetics, Vol. 53, Núm. 10, pp. 1405-1414

2020

  1. Involvement of the substance p/neurokinin-1 receptor system in oral pain and inflammation

    Journal of Biological Regulators and Homeostatic Agents

  2. Neurokinin receptor antagonism: a patent review (2014-present)

    Expert Opinion on Therapeutic Patents, Vol. 30, Núm. 7, pp. 527-539

  3. The neurokinin-1 receptor antagonist aprepitant, a new drug for the treatment of hematological malignancies: Focus on acute myeloid leukemia

    Journal of Clinical Medicine, Vol. 9, Núm. 6

  4. The neurokinin-1 receptor antagonist aprepitant: An intelligent bullet against cancer?

    Cancers, Vol. 12, Núm. 9, pp. 1-22

  5. The substance P and neurokinin-1 receptor system in human thyroid cancer: An immunohistochemical study

    European Journal of Histochemistry, Vol. 64, Núm. 2

  6. Triple Negative Breast Cancer: How Neurokinin-1 Receptor Antagonists Could Be Used as a New Therapeutic Approach

    Mini reviews in medicinal chemistry, Vol. 20, Núm. 5, pp. 408-417

2019

  1. Antipruritic vs. Antitumour action of aprepitant: A question of dose

    Acta Dermato-Venereologica

  2. Clinical presentation of individuals with human T-cell leukemia virus type-1 infection in Spain

    Open Forum Infectious Diseases, Vol. 6, Núm. 2

  3. Exploring target genes involved in the effect of quercetin on the response to oxidative stress in caenorhabditis elegans

    Antioxidants, Vol. 8, Núm. 12